Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for AKRO
| Stock Name | Akero Therapeutics Inc |
| Ticker | AKRO(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US00973Y1082 |
| LEI | 549300SI3KG74LBE2955 |
Show aggregate AKRO holdings
News associated with AKRO
- Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $81.57 Average Target Price from Analysts
- Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has received a consensus rating of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on the stock in […] - 2025-09-05 02:52:56
- Akero Therapeutics (NASDAQ:AKRO) Research Coverage Started at TD Cowen
- TD Cowen assumed coverage on shares of Akero Therapeutics (NASDAQ:AKRO – Free Report) in a research note published on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $76.00 target price on the stock. AKRO has been the subject of several other research reports. Citigroup dropped their price target on shares of […] - 2025-08-07 02:54:52
- Universal Beteiligungs und Servicegesellschaft mbH Invests $463,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO)
- Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 11,436 shares of the company’s stock, valued at approximately $463,000. A number of other […] - 2025-08-04 05:14:50
- KLP Kapitalforvaltning AS Cuts Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)
- KLP Kapitalforvaltning AS decreased its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 12.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,600 shares of the company’s stock after selling 1,400 shares during the […] - 2025-07-31 05:14:49
- Jennison Associates LLC Purchases Shares of 13,178 Akero Therapeutics, Inc. (NASDAQ:AKRO)
- Jennison Associates LLC bought a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 13,178 shares of the company’s stock, valued at approximately $533,000. Several other institutional investors and hedge funds have also […] - 2025-07-23 06:20:51
- Akero Therapeutics, Inc. (NASDAQ:AKRO) Position Increased by Bank of New York Mellon Corp
- Bank of New York Mellon Corp raised its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 6.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,665 shares of the company’s stock after acquiring an additional 12,235 shares […] - 2025-07-22 08:19:03
- Bank of New York Mellon Corp Acquires 12,235 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)
- Bank of New York Mellon Corp raised its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 6.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 212,665 shares of the company’s stock after buying an additional 12,235 shares during the quarter. Bank […] - 2025-07-22 07:24:51
- Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells $1,534,800.00 in Stock
- Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) CEO Andrew Cheng sold 30,000 shares of the company’s stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $51.16, for a total value of $1,534,800.00. Following the sale, the chief executive officer directly owned 520,757 shares of the company’s […] - 2025-07-14 06:16:53
- Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Consensus Recommendation of “Buy” by Brokerages
- Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has received a consensus recommendation of “Buy” from the six research firms that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last […] - 2025-07-14 05:38:47
- Mirae Asset Global Investments Co. Ltd. Purchases 338 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)
- Mirae Asset Global Investments Co. Ltd. grew its position in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 14.5% during the first quarter, HoldingsChannel reports. The firm owned 2,664 shares of the company’s stock after buying an additional 338 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Akero Therapeutics were worth […] - 2025-07-07 04:41:41
- Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $82.50 Average Target Price from Analysts
- Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have been assigned a consensus rating of “Buy” from the six analysts that are covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the […] - 2025-06-24 03:11:00
- Millennium Management LLC Sells 57,892 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)
- Millennium Management LLC decreased its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 77.6% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 16,736 shares of the company’s stock after selling 57,892 shares during the period. Millennium Management LLC’s holdings in Akero Therapeutics […] - 2025-06-10 05:18:54
- Akero Therapeutics Sees Unusually High Options Volume (NASDAQ:AKRO)
- Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) was the target of some unusual options trading on Monday. Stock traders bought 3,105 call options on the company. This represents an increase of approximately 106% compared to the average volume of 1,508 call options. Insider Activity In other news, insider Timothy Rolph sold 12,500 shares of […] - 2025-06-10 02:00:51
- Akero Therapeutics (NASDAQ:AKRO) Given New $64.00 Price Target at Bank of America
- Akero Therapeutics (NASDAQ:AKRO – Free Report) had its target price raised by Bank of America from $63.00 to $64.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. Other research analysts also recently issued research reports about the company. Citigroup reduced their price target on Akero Therapeutics […] - 2025-05-28 02:44:51
- ProShare Advisors LLC Grows Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)
- ProShare Advisors LLC boosted its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 32.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 22,398 shares of the company’s stock after acquiring an additional 5,477 shares during the period. ProShare Advisors LLC’s holdings in Akero Therapeutics were worth $623,000 as of […] - 2025-05-26 05:16:50
- Akero Therapeutics (NASDAQ:AKRO) Price Target Cut to $78.00 by Analysts at Citigroup
- Akero Therapeutics (NASDAQ:AKRO – Free Report) had its price objective decreased by Citigroup from $80.00 to $78.00 in a research note issued to investors on Tuesday,Benzinga reports. Citigroup currently has a buy rating on the stock. Several other analysts have also weighed in on AKRO. HC Wainwright raised their price objective on shares of Akero […] - 2025-05-14 04:58:49
- Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $76.29 Average Price Target from Analysts
- Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have earned a consensus recommendation of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued ratings on the stock […] - 2025-05-05 04:28:56
- Sterling Capital Management LLC Boosts Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)
- Sterling Capital Management LLC lifted its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 764.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,789 shares of the company’s stock after purchasing an additional 1,582 shares during the period. Sterling Capital Management LLC’s holdings in Akero […] - 2025-04-24 05:56:54
- Vanguard Group Inc. Has $103.06 Million Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)
- Vanguard Group Inc. raised its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 0.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 3,704,411 shares of the company’s stock after purchasing an additional 27,830 shares during the period. Vanguard Group Inc. owned approximately […] - 2025-04-10 04:38:50
- KLP Kapitalforvaltning AS Invests $306,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO)
- KLP Kapitalforvaltning AS acquired a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 11,000 shares of the company’s stock, valued at approximately $306,000. A number of other hedge funds and other institutional investors have also recently bought and sold shares of AKRO. Handelsbanken […] - 2025-04-07 05:06:49
- Akero Therapeutics (NASDAQ:AKRO) and Rezolute (NASDAQ:RZLT) Head to Head Comparison
- Rezolute (NASDAQ:RZLT – Get Free Report) and Akero Therapeutics (NASDAQ:AKRO – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Analyst Ratings This is a breakdown of recent ratings […] - 2025-03-26 04:10:42
- Y Intercept Hong Kong Ltd Lowers Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)
- Y Intercept Hong Kong Ltd lessened its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 47.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 8,950 shares of the company’s stock after selling 7,966 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Akero Therapeutics were worth $249,000 at […] - 2025-03-05 07:07:16
- Akero Therapeutics (NASDAQ:AKRO) Price Target Raised to $75.00
- Akero Therapeutics (NASDAQ:AKRO – Free Report) had its target price boosted by HC Wainwright from $72.00 to $75.00 in a report published on Monday morning,Benzinga reports. They currently have a buy rating on the stock. AKRO has been the topic of several other reports. Canaccord Genuity Group lifted their price target on shares of Akero […] - 2025-03-04 04:50:49
- Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock Position Decreased by Global Retirement Partners LLC
- Global Retirement Partners LLC lessened its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 13.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,917 shares of the company’s stock after selling 740 shares during the period. Global […] - 2025-02-27 06:52:59
- Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $75.86 Consensus Target Price from Analysts
- Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has been given an average recommendation of “Buy” by the nine analysts that are covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have covered the stock in the last […] - 2025-02-19 05:06:50
- Technology Stocks Upended by China’s DeepSeek
- The S&P 500 Index ($SPX ) (SPY ) Monday closed down -1.46%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.65%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.97%. March E-mini S&P futures (ESH25 ) are down by -1.38%, and March E-mini Nasdaq... - 2025-01-28 13:04:47
- Stocks Hit by AI Jitters
- The S&P 500 Index ($SPX ) (SPY ) today is down -1.64%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.68%. March E-mini S&P futures (ESH25 ) are down sharply by -1.70%, and March E-mini... - 2025-01-28 02:53:37
iShares MSCI World Small Cap UCITS ETF USD (Acc) AKRO holdings
| Date | Number of AKRO Shares Held | Base Market Value of AKRO Shares | Local Market Value of AKRO Shares | Change in AKRO Shares Held | Change in AKRO Base Value | Current Price per AKRO Share Held | Previous Price per AKRO Share Held |
|---|
| 2025-10-15 (Wednesday) | 40,913 | USD 2,192,937 | USD 2,192,937 | | | | |
| 2025-10-10 (Friday) | 40,664 | USD 2,190,976 | USD 2,190,976 | | | | |
| 2025-10-08 (Wednesday) | 40,664 | USD 1,890,469 | USD 1,890,469 | | | | |
| 2025-10-07 (Tuesday) | 40,664 | USD 1,870,544 | USD 1,870,544 | 166 | USD 6,016 | USD 46 | USD 46.04 |
| 2025-10-06 (Monday) | 40,498 | USD 1,864,528 | USD 1,864,528 | 0 | USD -2,430 | USD 46.04 | USD 46.1 |
| 2025-10-03 (Friday) | 40,498 | USD 1,866,958 | USD 1,866,958 | 0 | USD -12,554 | USD 46.1 | USD 46.41 |
| 2025-10-02 (Thursday) | 40,498 | USD 1,879,512 | USD 1,879,512 | 0 | USD -5,670 | USD 46.41 | USD 46.55 |
| 2025-10-01 (Wednesday) | 40,498 | USD 1,885,182 | USD 1,885,182 | 0 | USD -37,663 | USD 46.55 | USD 47.48 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of AKRO by Blackrock for IE00BF4RFH31
Show aggregate share trades of AKRO| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-07 | BUY | 166 | | | 46.000* | | 42.82 |
| 2025-09-08 | SELL | -332 | | | 44.570* | | 42.64 Profit of 14,156 on sale |
| 2025-08-15 | BUY | 164 | | | 49.380* | | 42.60 |
| 2025-08-07 | BUY | 492 | | | 50.450* | | 42.53 |
| 2025-07-29 | BUY | 164 | | | 47.490* | | 42.30 |
| 2025-07-14 | BUY | 332 | | | 52.730* | | 41.88 |
| 2025-06-30 | BUY | 328 | | | 53.360* | | 41.45 |
| 2025-06-25 | BUY | 492 | | | 55.040* | | 41.18 |
| 2025-06-23 | BUY | 4,898 | | | 54.030* | | 41.01 |
| 2025-06-20 | SELL | -72 | | | 54.200* | | 40.93 Profit of 2,947 on sale |
| 2025-06-12 | SELL | -576 | | | 53.560* | | 40.36 Profit of 23,247 on sale |
| 2025-06-02 | BUY | 219 | | | 50.730* | | 39.63 |
| 2025-05-28 | BUY | 144 | | | 45.320* | | 39.46 |
| 2025-05-14 | BUY | 73 | | | 37.880* | | 39.11 |
| 2025-05-13 | BUY | 146 | | | 40.010* | | 39.11 |
| 2025-05-07 | BUY | 216 | | | 42.790* | | 39.02 |
| 2025-04-28 | BUY | 72 | | | 42.170* | | 38.72 |
| 2025-04-16 | BUY | 949 | | | 37.440* | | 38.72 |
| 2025-04-14 | BUY | 146 | | | 37.600* | | 38.73 |
| 2025-04-08 | SELL | -146 | | | 34.040* | | 38.86 Profit of 5,674 on sale |
| 2025-04-04 | SELL | -146 | | | 36.730* | | 38.91 Profit of 5,681 on sale |
| 2025-03-28 | BUY | 730 | | | 42.720* | | 38.83 |
| 2025-03-12 | SELL | -146 | | | 45.850* | | 38.00 Profit of 5,549 on sale |
| 2025-03-04 | SELL | -144 | | | 44.530* | | 37.66 Profit of 5,423 on sale |
| 2025-02-26 | SELL | -288 | | | 47.590* | | 37.13 Profit of 10,695 on sale |
| 2025-02-13 | BUY | 73 | | | 49.230* | | 35.38 |
| 2025-02-12 | BUY | 292 | | | 49.440* | | 35.17 |
| 2025-01-28 | BUY | 75 | | | 51.470* | | 31.35 |
| 2025-01-23 | BUY | 75 | | | 26.160* | | 31.15 |
| 2024-12-09 | BUY | 2,700 | | | 31.120* | | 31.42 |
| 2024-12-04 | BUY | 150 | | | 30.920* | | 31.48 |
| 2024-12-03 | BUY | 222 | | | 30.750* | | 31.50 |
| 2024-11-19 | BUY | 450 | | | 31.030* | | 31.43 |
| 2024-11-18 | BUY | 150 | | | 29.560* | | 31.49 |
| 2024-11-12 | BUY | 296 | | | 32.380* | | 31.46 |
| 2024-11-11 | BUY | 74 | | | 33.040* | | 31.35 |
| 2024-11-11 | BUY | 74 | | | 33.040* | | 31.35 |
| 2024-11-07 | BUY | 365 | | | 34.870* | | 30.79 |
| 2024-11-07 | BUY | 365 | | | 34.870* | | 30.79 |
| 2024-10-23 | BUY | 146 | | | 28.670* | | 30.03 |
| 2024-10-23 | BUY | 146 | | | 28.670* | | 30.03 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of AKRO
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 320,554 | 0 | 439,677 | 72.9% |
| 2025-09-18 | 580,318 | 8,000 | 1,504,420 | 38.6% |
| 2025-09-17 | 204,882 | 20 | 453,803 | 45.1% |
| 2025-09-16 | 206,796 | 20 | 330,745 | 62.5% |
| 2025-09-15 | 220,059 | 26 | 481,701 | 45.7% |
| 2025-09-12 | 353,794 | 0 | 539,619 | 65.6% |
| 2025-09-11 | 255,450 | 91 | 523,792 | 48.8% |
| 2025-09-10 | 448,340 | 7,548 | 553,346 | 81.0% |
| 2025-09-09 | 151,462 | 14,540 | 268,131 | 56.5% |
| 2025-09-08 | 190,270 | 26,862 | 376,993 | 50.5% |
| 2025-09-05 | 117,683 | 0 | 243,944 | 48.2% |
| 2025-09-04 | 194,348 | 29 | 609,138 | 31.9% |
| 2025-09-03 | 127,854 | 3 | 245,662 | 52.0% |
| 2025-09-02 | 116,986 | 3,904 | 277,827 | 42.1% |
| 2025-08-29 | 85,173 | 0 | 146,209 | 58.3% |
| 2025-08-28 | 122,035 | 238 | 187,638 | 65.0% |
| 2025-08-27 | 153,819 | 113 | 232,967 | 66.0% |
| 2025-08-26 | 92,304 | 4,102 | 207,519 | 44.5% |
| 2025-08-25 | 96,706 | 0 | 144,623 | 66.9% |
| 2025-08-22 | 146,180 | 0 | 328,681 | 44.5% |
| 2025-08-21 | 99,543 | 200 | 166,233 | 59.9% |
| 2025-08-20 | 186,444 | 0 | 265,086 | 70.3% |
| 2025-08-19 | 135,620 | 0 | 193,668 | 70.0% |
| 2025-08-18 | 108,395 | 0 | 171,507 | 63.2% |
| 2025-08-15 | 554,663 | 5 | 878,289 | 63.2% |
| 2025-08-14 | 325,703 | 13,249 | 531,753 | 61.3% |
| 2025-08-13 | 127,086 | 0 | 277,108 | 45.9% |
| 2025-08-12 | 187,432 | 30,605 | 288,844 | 64.9% |
| 2025-08-11 | 293,883 | 13,502 | 490,123 | 60.0% |
| 2025-08-08 | 199,064 | 0 | 355,719 | 56.0% |
| 2025-08-07 | 275,529 | 0 | 721,339 | 38.2% |
| 2025-08-06 | 963,438 | 211 | 1,390,492 | 69.3% |
| 2025-08-05 | 318,638 | 4,289 | 433,703 | 73.5% |
| 2025-08-04 | 238,397 | 92 | 375,442 | 63.5% |
| 2025-08-01 | 223,655 | 714 | 301,118 | 74.3% |
| 2025-07-31 | 224,466 | 97 | 335,691 | 66.9% |
| 2025-07-30 | 131,329 | 0 | 227,512 | 57.7% |
| 2025-07-29 | 99,368 | 49 | 195,575 | 50.8% |
| 2025-07-28 | 169,588 | 7 | 309,206 | 54.8% |
| 2025-07-25 | 92,231 | 60 | 188,784 | 48.9% |
| 2025-07-24 | 79,791 | 65 | 200,044 | 39.9% |
| 2025-07-23 | 133,901 | 77 | 303,687 | 44.1% |
| 2025-07-22 | 82,616 | 50 | 289,833 | 28.5% |
| 2025-07-21 | 89,737 | 216 | 210,901 | 42.5% |
| 2025-07-18 | 95,387 | 211 | 239,968 | 39.7% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.